The role of enoyl-CoA hydratase short chain 1 and peroxiredoxin 3 in PP2-induced apoptosis in human breast cancer MCF-7 cells

FEBS Letters

Volumn 584, Issue 14, 2010, Pages 3185-3192

  Liu, Xiang ^a   Feng, Renqing ^a   Du, Liying ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

4 Amino 5 (4 chlorophenyl) 7 (t butyl)pyrazolo 3,4 d pyrimidine; Apoptosis; Breast cancer; Enoyl CoA hydratase short chain 1; Peroxiredoxin 3

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ENOYL COENZYME A HYDRATASE; ENOYL COENZYME A HYDRATASE SHORT CHAIN 1; PEROXIREDOXIN 3; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; PEROXIREDOXIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOSIS INHIBITION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING; BREAST TUMOR; CELL; CELL STRUCTURE; DRUG EFFECT; FEMALE; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELLS; CELLULAR STRUCTURES; DOWN-REGULATION; ENOYL-COA HYDRATASE; FEMALE; HUMANS; PEROXIREDOXINS;

EID: 77954176099     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2010.06.002     Document Type: Article

References (34)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
2. Clarke R., Skaar T.C., Bouker K.B., Davis N., Lee Y.R., Welch J.N., Leonessa F. Molecular and pharmacological aspects of antiestrogen resistance. J. Steroid Biochem. Mol. Biol. 2001, 76:71-84.
3. Clarke R., et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003, 22:7316-7339.
4. Alvarez R.H., Kantarjian H.M., Cortes J.E. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 2006, 107:1918-1929.
5. Summy J.M., Gallick G.E. Treatment for advanced tumors: SRC reclaims center stage. Clin. Cancer Res. 2006, 12:1398-1401.
6. Giaccone G., Zucali P.A. Src as a potential therapeutic target in non-small-cell lung cancer. Ann. Oncol. 2008, 19:1219-1223.
7. Rucci N., Susa M., Teti A. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med. Chem. 2008, 8:342-349.
8. Golas J.M., et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003, 63:375-381.
9. Lee D., Gautschi O. Clinical development of SRC tyrosine kinase inhibitors in lung cancer. Clin. Lung Cancer 2006, 7:381-384.
10. Hanke J.H., Gardner J.P., Dow R.L., Changelian P.S., Brissette W.H., Weringer E.J., Pollok B.A., Connelly P.A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 1996, 271:695-701.
11. Lee M., Kim J.Y., Koh W.S. Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia. J. Cell. Biochem. 2004, 93:629-638.
12. Beierle E.A., Ma X., Trujillo A., Kurenova E.V., Cance W.G., Golubovskaya V.M. Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines. Mol. Carcinog. 2000, 49:224-234.
13. Wang B.C., Wang H.X., Feng J.X., Meng D.Z., Qu L.J., Zhu Y.X. Post-translational modifications, but not transcriptional regulation, of major chloroplast RNA-binding proteins are related to Arabidopsis seedling development. Proteomics 2006, 6:2555-2563.
14. Shevchenko A., Wilm M., Vorm O., Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996, 68:850-858.
15. Nam J.S., Ino Y., Sakamoto M., Hirohashi S. Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin. Cancer Res. 2002, 8:2430-2436.
16. Wang Y., He Q.Y., Sun R.W., Che C.M., Chiu J.F. GoldIII porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res. 2005, 65:11553-11564.
17. Zhou J., Zhang S., Ong C.N., Shen H.M. Critical role of pro-apoptotic Bcl-2 family members in andrographolide-induced apoptosis in human cancer cells. Biochem. Pharmacol. 2006, 72:132-144.
18. Jackson S., Schaefer J., Middleton B., Turnbull D.M. Characterisation of a novel enzyme of human fatty acid beta-oxidation: a matrix-associated, mitochondrial 2-enoyl-CoA hydratase. Biochem. Biophys. Res. Commun. 1995, 214:247-253.
19. Agnihotri G., Liu H.W. Enoyl-CoA hydratase. Reaction, mechanism, and inhibition. Bioorg. Med. Chem. 2003, 11:9-20.
20. Huang T.C., Chang H.Y., Hsu C.H., Kuo W.H., Chang K.J., Juan H.F. Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B. J. Proteome Res. 2008, 7:1433-1444.
21. Nonn L., Berggren M., Powis G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol. Cancer Res. 2003, 1:682-689.
22. Noh D.Y., Ahn S.J., Lee R.A., Kim S.W., Park I.A., Chae H.Z. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res. 2001, 21:2085-2090.
23. Kinnula V.L., Lehtonen S., Sormunen R., Kaarteenaho-Wiik R., Kang S.W., Rhee S.G., Soini Y. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J. Pathol. 2002, 196:316-323.
24. Kim R., Emi M., Tanabe K. Caspase-dependent and -independent cell death pathways after DNA damage (Review). Oncol. Rep. 2005, 14:595-599.
25. Gross A., McDonnell J.M., Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999, 13:1899-1911.
26. Raisova M., et al. The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J. Invest. Dermatol. 2001, 117:333-340.
27. Gao C.F., Ren S., Zhang L., Nakajima T., Ichinose S., Hara T., Koike K., Tsuchida N. Caspase-dependent cytosolic release of cytochrome c and membrane translocation of Bax in p53-induced apoptosis. Exp. Cell Res. 2001, 265:145-151.
28. De Giorgi F., et al. The permeability transition pore signals apoptosis by directing Bax translocation and multimerization. FASEB J. 2002, 16:607-609.
29. Tsuruta F., Masuyama N., Gotoh Y. The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria. J. Biol. Chem. 2002, 277:14040-14047.
30. Yamaguchi H., Wang H.G. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 2001, 20:7779-7786.
31. Yang S.-J., Chang S.-C., Wen H.-C., Chen C.-Y., Liao J.-F., Chang C.-H. Plumbagin activates ERK1/2 and Akt via superoxide, Src and PI3-kinase in 3T3-L1 Cells. Eur. J. Pharmacol. 2010, 638:21-28.
32. Meng X.N., et al. Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br. J. Cancer 2009, 101:327-334.
33. Zheng Y., Yamaguchi H., Tian C., Lee M.W., Tang H., Wang H.G., Chen Q. Arsenic trioxide (As(2)O(3)) induces apoptosis through activation of Bax in hematopoietic cells. Oncogene 2005, 24:3339-3347.
34. Chen Q., Chai Y.C., Mazumder S., Jiang C., Macklis R.M., Chisolm G.M., Almasan A. The late increase in intracellular free radical oxygen species during apoptosis is associated with cytochrome c release, caspase activation, and mitochondrial dysfunction. Cell Death Differ. 2003, 10:323-334.